Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 92Myelodysplastic Syndromes 59Leukemia 30Leukemia, Myelomonocytic, Chronic 27Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Multiple Myeloma 8Recurrence 7Lymphoma 7Primary Myelofibrosis 6Myeloproliferative Disorders 5Hematologic Neoplasms 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Acute 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Breast Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Pancreatic Neoplasms 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Renal Insufficiency 2

Interventions

eprenetapopt 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × MDS × Azacitidine × Clear all
NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

Phase 3 Completed
154 enrolled 10 charts

MDS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡